Trevena, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRVN research report →
Companywww.trevena.com
Trevena, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
- CEO
- Carrie L. Bourdow
- IPO
- 2014
- Employees
- 23
- HQ
- Chesterbrook, PA, US
Price Chart
Valuation
- Market Cap
- $9.50K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -0.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 46.56%
- Op Margin
- -1129.22%
- Net Margin
- -1289.25%
- ROE
- -1014.58%
- ROIC
- -103.60%
Growth & Income
- Revenue
- $3.13M · 847.61%
- Net Income
- $-40,289,000 · 24.93%
- EPS
- $-3.16 · 58.37%
- Op Income
- $-35,288,000
- FCF YoY
- 35.78%
Performance & Tape
- 52W High
- $1.93
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.42
- Beta
- 0.56
- Avg Volume
- 734
Get TickerSpark's AI analysis on TRVN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 26, 24 | Sutton Katrine | other | 0 |
| Nov 26, 24 | Sutton Katrine | other | 76 |
| Oct 8, 24 | Demitrack Mark | other | 20 |
| Oct 8, 24 | Demitrack Mark | other | 45 |
| Oct 8, 24 | Demitrack Mark | other | 144 |
| Oct 8, 24 | Demitrack Mark | other | 144 |
| Oct 8, 24 | Demitrack Mark | other | 532 |
| Oct 8, 24 | Shin Barry | other | 17 |
| Oct 8, 24 | Shin Barry | other | 41 |
| Oct 8, 24 | Shin Barry | other | 130 |
Our TRVN Coverage
We haven't published any research on TRVN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TRVN Report →